Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00457418 | High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2) | completed | Phase 1 | 32 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT01409174 | IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma | terminated | Phase 1 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT00658892 |
| Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma |
| completed |
| Phase 1 |
| 7 |
| Mayo ClinicOTHER |
| 1 |
| May 25, 2017 |
| clinicaltrials |
| NCT01843738 | Radiation Use During Vemurafenib Treatment | withdrawn | Phase 1 | 0 | University of UtahOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT01496807 | Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma | completed | Phase 1 | 31 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00871481 | Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT01760499 | Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study | completed | Phase 1 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT00940004 | Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients | completed | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01530698 | Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients | completed | Phase 1 / Phase 2 | 28 | Radboud University Medical CenterOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT02413827 | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma | terminated | Phase 1 / Phase 2 | 9 | Celldex TherapeuticsINDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01611675 | Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma | terminated | Phase 1 | 3 | Massachusetts General HospitalOTHER | 1 | Apr 6, 2017 | clinicaltrials |
| NCT01026324 | Dinaciclib in Treating Patients With Stage III-IV Melanoma | terminated | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2017 | clinicaltrials |
| NCT01065467 | Panobinostat (LBH589) in Patients With Metastatic Melanoma | completed | Phase 1 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT01844674 | A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies | completed | Phase 1 | 18 | Hoffmann-La RocheINDUSTRY | 5 | Mar 20, 2017 | clinicaltrials |
| NCT00398073 | Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | completed | Phase 1 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT01390818 | Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 146 | EMD SeronoINDUSTRY | 3 | Mar 7, 2017 | clinicaltrials |
| NCT00861406 | Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine | completed | Phase 1 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00418496 | Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma | completed | Phase 1 | 17 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00553306 | Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma | completed | Phase 1 / Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01121718 | NIR-Guided Sentinel Lymph Node Mapping in Melanoma | completed | Phase 1 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT02406183 | Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma | completed | Phase 1 | 13 | RadiotherapieOTHER | 1 | Jan 10, 2017 | clinicaltrials |
| NCT01984255 | A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients | terminated | Phase 1 | 3 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 29, 2016 | clinicaltrials |
| NCT01189383 | IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 20 | Baylor Research InstituteOTHER | 1 | Dec 22, 2016 | clinicaltrials |
| NCT00705640 | Vaccine Therapy in Treating Patients With Advanced Melanoma(Mel48) | completed | Phase 1 | 45 | Craig L Slingluff, JrOTHER | 1 | Dec 16, 2016 | clinicaltrials |
| NCT00977145 | Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma(Mel 51) | terminated | Phase 1 | 11 | Craig L Slingluff, JrOTHER | 1 | Dec 16, 2016 | clinicaltrials |
| NCT01264731 | Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma(MEL53) | completed | Phase 1 | 4 | University of VirginiaOTHER | 1 | Dec 16, 2016 | clinicaltrials |
| NCT01765543 | A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf) | completed | Phase 1 | 27 | Hoffmann-La RocheINDUSTRY | 5 | Dec 15, 2016 | clinicaltrials |
| NCT02990416 | A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma | unknown | Phase 1 / Phase 2 | 63 | Virogen Biotechnology Inc.INDUSTRY | 1 | Dec 13, 2016 | clinicaltrials |
| NCT00256230 | Disulfiram in Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 7 | John P. FruehaufOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT01690377 | Natural Dendritic Cell Vaccines in Metastatic Melanoma Patients | completed | Phase 1 | 30 | Radboud University Medical CenterOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT00765921 | Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma | completed | Phase 1 | 40 | Massachusetts Eye and Ear InfirmaryOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT01888081 | A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma | terminated | Phase 1 / Phase 2 | 2 | Virogen Biotechnology Inc.INDUSTRY | 1 | Nov 23, 2016 | clinicaltrials |
| NCT01950195 | SRS (Stereotactic Radiosurgery) Plus Ipilimumab | terminated | Phase 1 | 4 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT01522664 | A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma | completed | Phase 1 | 53 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01765556 | A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma | withdrawn | Phase 1 | 0 | Hoffmann-La RocheINDUSTRY | 0 | Nov 2, 2016 | clinicaltrials |
| NCT01849666 | A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | completed | Phase 1 | 2 | Hoffmann-La RocheINDUSTRY | 5 | Nov 2, 2016 | clinicaltrials |
| NCT01851824 | A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | completed | Phase 1 | 9 | Hoffmann-La RocheINDUSTRY | 9 | Nov 2, 2016 | clinicaltrials |
| NCT01039844 | Study of Weekly LOC-paclitaxel Injection for Melanoma | terminated | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 27, 2016 | clinicaltrials |
| NCT01133977 | E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma | completed | Phase 1 / Phase 2 | 97 | Eisai Inc.INDUSTRY | 5 | Oct 10, 2016 | clinicaltrials |
| NCT01519323 | BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations | terminated | Phase 1 | 6 | Hoffmann-La RocheINDUSTRY | 10 | Oct 10, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | terminated | Phase 1 | 155 | Mirna Therapeutics, Inc.INDUSTRY | 2 | Sep 27, 2016 | clinicaltrials |
| NCT02862145 | Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions(MRX34-102) | withdrawn | Phase 1 / Phase 2 | 0 | Mirna Therapeutics, Inc.INDUSTRY | 0 | Sep 27, 2016 | clinicaltrials |
| NCT01777776 | Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. | terminated | Phase 1 / Phase 2 | 28 | Array BioPharmaINDUSTRY | 4 | Sep 13, 2016 | clinicaltrials |
| NCT01935453 | A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer | completed | Phase 1 | 18 | OrienGene Biotechnology Ltd.INDUSTRY | 1 | Sep 1, 2016 | clinicaltrials |
| NCT00580320 | Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma | completed | Phase 1 | 17 | Virginia Commonwealth UniversityOTHER | 1 | Aug 18, 2016 | clinicaltrials |
| NCT01278940 | Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma | completed | Phase 1 / Phase 2 | 31 | Oslo University HospitalOTHER | 0 | Aug 15, 2016 | clinicaltrials |
| NCT01585350 | A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients(MEL58) | completed | Phase 1 | 53 | Craig L Slingluff, JrOTHER | 1 | Aug 12, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jun 7, 2017source: clinicaltrials